FIELD: biotechnology.
SUBSTANCE: disclosed is a composition containing one or more viral vectors coding CRISPR/Cas system for use in treating a disease or cerebral disorder.
EFFECT: said system due to the presence of at least one nuclear localization signal (NLS) enables efficient editing of the eukaryotic cell genome, in connection with which it can be used to edit genes associated with cerebral diseases in mammals.
20 cl, 85 dwg, 18 tbl, 40 ex
Title | Year | Author | Number |
---|---|---|---|
DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED ACTION AND MODELING OF DISEASES AND DISORDERS OF POSTMITOTIC CELLS | 2014 |
|
RU2725502C2 |
DELIVERY, CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND USE IN THERAPY | 2013 |
|
RU2721275C2 |
NOVEL ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2737537C2 |
SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES | 2016 |
|
RU2812491C2 |
THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
COMPOSITIONS CONTAINING CURONES AND WAYS OF APPLICATION THEREOF | 2018 |
|
RU2822800C2 |
Authors
Dates
2020-03-11—Published
2014-06-11—Filed